Cardiovascular events in patients under age fifty with early findings of elevated lipid and glucose levels - The AMORIS study

PLoS One. 2018 Aug 23;13(8):e0201972. doi: 10.1371/journal.pone.0201972. eCollection 2018.

Abstract

Background: The long-term trajectories of lipid and glucose levels in subjects who experience a major cardiovascular (CV) event at a young age has not been well studied. Our objective was to investigate lipid, lipoprotein, apolipoprotein (apo), and glucose levels in individuals experiencing a CV event before 50 years of age.

Methods and findings: A first CV event [non-fatal myocardial infarction (MI), coronary revascularisation, or CV related death] before age 50 was recorded in 2,939 (cumulative incidence 1.2% in males and 0.3% in females) of 361,353 individuals included in the prospective Swedish AMORIS (Apolipoprotein-related MOrtality RISk) study with health examinations 1985-1996 and follow-up through 2011. In a nested case-control analysis, cases with a CV event were matched to randomly selected controls. Population risk factor trajectories were calculated up to 20 years prior to an event. Total cholesterol (TC), triglyceride (TG), and glucose levels were higher in cases than in controls as early as 20 years prior to the event with differences increasing over time. Low density lipoprotein, apoB, and the apoB/apoA-1 ratio were higher and increased over time, while HDL and apoA-1 were lower in cases compared to controls. The odds ratio was 2.5 (95% confidence interval 1.6-3.7) for TC ≥5 mmol/L and TG ≥1.7 mmol/L in cases versus controls. The adjusted population-attributable fractions including lipids, glucose, diabetes, smoking, hypertension, and obesity indicated that about 50% of CV events before age 50 may be associated with elevated lipid and glucose levels.

Conclusions: Elevated TC, TG, LDL, apoB, and glucose levels and high apoB/apo A-1 ratio documented two decades before a CV event in subjects younger than 50 years may account for about half of CV events before age 50, which calls for early recognition and possibly treatment of modifiable CV risk factors in young individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Apolipoproteins / blood
  • Biomarkers
  • Blood Glucose*
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / epidemiology*
  • Case-Control Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Lipids / blood*
  • Lipoproteins / blood
  • Male
  • Middle Aged
  • Odds Ratio
  • Public Health Surveillance
  • Risk Factors

Substances

  • Apolipoproteins
  • Biomarkers
  • Blood Glucose
  • Lipids
  • Lipoproteins

Grants and funding

The Gunnar and Ingmar Jungner Foundation is a non-commercial foundation with a primary goal to fund laboratory medicine and medical research. This foundation has contributed to the establishment of the AMORIS cohort at Karolinska Institutet and also provided a non-restricted grant to the Institute of Environmental Medicine, Karolinska Institutet for research based on this cohort. The foundation has not made any claims or suggestions as to the contents of this research or had any influence on the work on the current manuscript. The chair of the foundation, Associate Professor Ingmar Jungner, is co-author of this manuscript based on his expertise in laboratory medicine. The foundation was registered in Stockholm, Sweden 1998-03-02 (No. 671-97-14421) (GW).